DCM
ANAB icon

Diag Capital Management’s AnaptysBio ANAB Stock Holding History

Diag Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$95K Buy
+1,493
New +$111K 0.11% 40

Other funds holding ANAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Diag Capital Management's ANAB Position: Q4 2018 in Review

Diag Capital Management opened a new position in AnaptysBio (ANAB) in Q4 2018: 1,493 shares worth $95K. The stake represents 0.11% of the portfolio and ranks #40 among its holdings.

121 funds tracked by Wall St. Rank hold ANAB as of Q4 2018.

  • Diag Capital Management held 1,493 shares of AnaptysBio worth $95K as of Q4 2018.
  • AnaptysBio was a new Diag Capital Management position in Q4 2018.
  • AnaptysBio made up 0.11% of Diag Capital Management's portfolio in Q4 2018, its #40 holding.
  • 121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.